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A B S T R A C T
Background
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease associated
with substantial morbidity and mortality. The objective of this study was to determine whether
there is a peripheral blood protein signature in IPF and whether components of this signature
may serve as biomarkers for disease presence and progression.
Methods and Findings
We analyzed the concentrations of 49 proteins in the plasma of 74 patients with IPF and in
the plasma of 53 control individuals. We identified a combinatorial signature of five proteins—
MMP7, MMP1, MMP8, IGFBP1, and TNFRSF1A—that was sufficient to distinguish patients from
controls with a sensitivity of 98.6% (95% confidence interval [CI] 92.7%–100%) and specificity of
98.1% (95% CI 89.9%–100%). Increases in MMP1 and MMP7 were also observed in lung tissue
and bronchoalveolar lavage fluid obtained from IPF patients. MMP7 and MMP1 plasma
concentrations were not increased in patients with chronic obstructive pulmonary disease or
sarcoidosis and distinguished IPF compared to subacute/chronic hypersensitivity pneumonitis,
a disease that may mimic IPF, with a sensitivity of 96.3% (95% CI 81.0%–100%) and specificity of
87.2% (95% CI 72.6%–95.7%). We verified our results in an independent validation cohort
composed of patients with IPF, familial pulmonary fibrosis, subclinical interstitial lung disease
(ILD), as well as with control individuals. MMP7 and MMP1 concentrations were significantly
higher in IPF patients compared to controls in this cohort. Furthermore, MMP7 concentrations
were elevated in patients with subclinical ILD and negatively correlated with percent predicted
forced vital capacity (FVC%) and percent predicted carbon monoxide diffusing capacity
(DLCO%).
Conclusions
Our experiments provide the first evidence for a peripheral blood protein signature in IPF to
our knowledge. The two main components of this signature, MMP7 and MMP1, are
overexpressed in the lung microenvironment and distinguish IPF from other chronic lung
diseases. Additionally, increased MMP7 concentration may be indicative of asymptomatic ILD
and reflect disease progression.
The Editors’ Summary of this article follows the references.
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Introduction
Idiopathic pulmonary fibrosis (IPF), a progressive fibrotic
interstitial lung disease (ILD) with median survival of 2.5–3 y,
is largely unaffected by currently available medical therapies
[1]. The disease is characterized by alveolar epithelial cell
injury and activation, fibroblast/myofibroblast foci formation,
and exaggerated accumulation of extracellular matrix in the
lung parenchyma. Recent studies employing high-throughput
genomic technologies to analyze samples from IPF patients or
genetically modified animals have highlighted the complexity
of the pathways involved in the disease (reviewed in [2–4]).
While these studies have improved the understanding of the
molecular mechanisms underlying lung fibrosis, they did not
translate well into the clinical arena.
Identification of peripheral blood biomarkers may facili-
tate the diagnosis and follow-up of patients with IPF as well as
the implementation of new therapeutic interventions. Cur-
rently, establishing a diagnosis of IPF may require surgical
lung biopsy in patients with atypical clinical presentations or
high-resolution computed tomography (HRCT) scans. Pa-
tients with IPF are often evaluated by serial pulmonary
physiology measurements and repeated radiographic exami-
nations. These studies provide a general assessment of the
extent of disease, but do not provide information about
disease activity on a molecular level. Higher serum concen-
trations of surfactant proteins [5], KL-6 [6], FASL [7], CCL-2
[8], a-defensins [9], and most recently SPP1 [10] have been
reported in patients with IPF and other ILDs, but most of
these studies were modest in size and assayed only a single or
a few protein markers simultaneously.
In this study, we used a multianalyte protein assay system to
simultaneously measure concentrations of 49 plasma pro-
teins, including cytokines, chemokines, growth and angio-
genic factors, matrix metalloproteases (MMPs), and markers
of apoptosis in a derivation cohort comprised of IPF patients
and healthy controls. We identified a combinatorial signature
of five proteins; of these, we measured concentrations of two
metalloproteases, MMP7 and MMP1, in other chronic lung
diseases and compared them to the levels observed in IPF
patients. Finally, the potential role of MMP7 and MMP1 as
IPF peripheral blood biomarkers was tested in an independ-
ent validation cohort.
Methods
For detailed description of the methods used in this study,
see Text S1.
Initial IPF Derivation Cohort
This study included 74 patients with IPF evaluated at the
University of Pittsburgh Medical Center. The diagnosis of IPF
was established on the basis of published criteria [11], and
surgical lung biopsy when clinically indicated [12] (see Text
S1). Clinical data were available through the Simmons Center
database. Smoking status was defined as previously described
[13]. Fifty-three control individuals were obtained from the
pulmonary division sample collection core. Baseline demo-
graphic information is detailed in Table 1. The mean percent
predicted forced vital capacity (FVC%) of IPF patients was
61.9 6 20.8; mean percent predicted carbon monoxide
diffusing capacity (DLCO%) was 42.1 6 17.4.
Chronic Obstructive Pulmonary Disease
Plasma samples from 73 patients with chronic obstructive
pulmonary disease (COPD) evaluated at the University of
Pittsburgh were available for this study. Individuals were
clinically stable at the time of examination, had tobacco
exposure of at least ten pack years, and had no clinical
diagnosis of rheumatologic, infectious, or other systemic
inflammatory disease. Disease severity was measured using
the GOLD classification as previously described [14]. The
COPD cohort included 13 patients with GOLD class 0–I, 21
patients with GOLD II, and 39 patients with GOLD III–IV.
Sarcoidosis
Plasma samples from 47 patients with sarcoidosis evaluated
at the University of Pittsburgh Medical Center were tested.
Patients with lung disease (n ¼ 29) demonstrated an average
FVC% of 76.7 6 22.1, and average DLCO% of 72.9 6 25.5.
The diagnosis and staging of disease was determined
according to American Thoracic Society and European
Respiratory Society criteria, as previously described [15,16].
Hypersensitivity Pneumonitis
Serum samples from 41 patients with subacute/chronic
hypersensitivity pneumonitis (HP) and 34 patients with IPF
evaluated at Instituto Nacional de Enfermedades Respira-
torias in Mexico were available for this study. Diagnosis of IPF
Table 1. Derivation Cohort Patient Characteristics
Variables Characteristics IPF (n ¼ 74) Control (n ¼ 53)
Sex Male 49 (66.2%) 22 (41.5%)
Female 25 (33.8%) 31 (58.5%)
Race European descent 73 (98.6%) 47 (88.7%)
African American 1 (1.4%) 4 (7.5%)
Unknown 0 (0.0%) 2 (3.8%)
Smoking Current 2 (2.7%) 3 (5.7%)
Former 56 (75.7%) 22 (41.5%)
Never 16 (21.6%) 26 (49.1%)
Unknown 0 (0.0%) 2 (3.8%)
Age (y) Mean þ SD 65.9 6 9.4 50.5 6 15.7
doi:10.1371/journal.pmed.0050093.t001
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and HP has been previously described for this cohort [17,18].
Briefly, HP patients showed the following features: (a)
antecedent bird exposure and positive serum antibodies
against avian antigens; (b) clinical and functional features of
ILD; (c) HRCT showing diffuse centrilobular poorly defined
micronodules, ground glass attenuation, focal air trapping,
and mild to moderate fibrotic changes; and (d) greater than
35% lymphocytes in bronchoalveolar lavage (BAL) fluid.
Forty-four percent of the patients had a surgical lung biopsy;
in all cases lung histology was consistent with the diagnosis of
HP. The average FVC% was 60.3 6 15.3 for HP and 59.1 6
17.2 for IPF patients.
Independent Validation Cohort
Serum samples from 20 control individuals, eight patients
with subclinical idiopathic ILD, 16 patients with familial
pulmonary fibrosis, and nine with sporadic IPF, evaluated at
the Warren Grant Magnuson Clinical Center of the National
Institutes of Health (NIH), were available for this study.
Patients with subclinical disease were first-degree relatives of
patients with familial pulmonary fibrosis; they were asympto-
matic, with normal pulmonary function tests but HRCT
findings consistent with early ILD. Familial pulmonary
fibrosis was defined as previously described [19]. Normal
volunteers were used as controls.
These cohorts have been previously described by us [20,21].
Briefly, the mean FVC% values for patients with sporadic IPF
and familial pulmonary fibrosis were 59.4 6 19.7 and 75.7 6
16.7, respectively. Eight patients with familial pulmonary
fibrosis were diagnosed with early asymptomatic ILD using
HRCT [21]; the mean FVC% in this group was 101.3 6 10.1.
Gender, age, ethnic origin, and smoking status for all groups
are presented in Table 2.
Lung tissue samples for microarray analysis were obtained
through the University of Pittsburgh Health Sciences Tissue
Bank as we previously described [22]. Twenty-three samples
were obtained from surgical remnants of biopsies or lungs
explanted from patients with IPF who underwent pulmonary
transplant and 14 control normal lung tissues obtained from
the disease free margins with normal histology of lung cancer
resection specimens. The morphologic diagnosis of IPF was
based on typical microscopic findings consistent with usual
interstitial pneumonia [12,23]. All patients fulfilled the
diagnostic criteria for IPF outlined by the American Thoracic
Society and European Respiratory Society [11].
All studies were approved by the Institutional Review
Board at the University of Pittsburgh, the National Heart,
Lung, and Blood Institute, or the National Institute of
Respiratory Diseases, Mexico. Informed consent was obtained
from all patients.
Blood Samples
Blood (45 ml) was drawn from participants using stand-
ardized phlebotomy procedures. Plasma or serum was
separated by centrifugation, and all specimens were imme-
diately aliquoted and frozen.
BAL
BAL was performed through flexible fiberoptic broncho-
scopy as part of the diagnostic process, as we previously
described [18,22,24]. Supernatants were kept at 70 8C until
use. BAL samples from 22 IPF patients (age 62.2 6 7.2 y) and
ten normal controls (age 41.5 6 5 y) were available for this
study.
Multiplex Analysis
Assays were performed using Luminex xMAP technology
(Luminex Corporation) in 96-well microplate format accord-
ing to appropriate manufacturers’ protocols (Invitrogen and
R&D Systems), as previously described [25] and in Text S1.
Bead-Based Immunoassays
A 34-plex assay was performed for IL1A, IL1RA, IL1B, IL2,
IL2R, IL4, IL5, IL6, IL7, IL8, IL10, IL12B, IL13, IL15, IL17,
TNFA, IFNA, IFNG, GMCSF, EGF, VEGF, GCSF, FGF2, HGF,
CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL11,
TNFRS1A, TNFRS1B, and TRAIL-R2 (Invitrogen). MMP
assays included MMP1, MMP2, MMP3, MMP7, MMP8,
MMP9, MMP12, and MMP13 (R&D Systems).
Assays for FAS, EGFR, FASL, Cyfra 21–1 (CKRT19 frag-
ment), IGFBP1, and KLK10 were developed in our Pittsburgh
Luminex Core Facility. The assays were validated as described
[25].
ELISA
Quantitative sandwich enzyme immunoassay for human
MMP1, MMP7, and AGER was performed as recommended by
the manufacturer (R&D Systems).
Oligonucleotide Microarray Experiments
Detailed information is provided in Text S1. Briefly, total
RNA was used as a template for synthesis of cDNA as
Table 2. Validation Cohort Patient Characteristics
Variables Characteristics Sporadic IPF (n ¼ 9) Control (n ¼ 20) Subclinical ILD (n ¼ 8) Familial IPF (n ¼ 16)
Sex Male 2 (22%) 9 (45%) 6 (75%) 7 (44%)
Female 7 (78%) 11 (55%) 2 (25%) 9 (56%)
Race European descent 7 (78%) 15 (75%) 7 (87%) 15 (94%)
Hispanic 0 (0%) 1 (5%) 1 (13%) 1 (6%)
Asian 2 (22%) 1 (5%) 0 (0%) 0 (0%)
African American 0 (0%) 3 (15%) 0 (0%) 0 (0%)
Smoking Current 0 (0%) 0 (0%) 2 (24%) 2 (18%)
Former 3 (33%) 6 (30%) 1 (13%) 6 (35%)
Never 6 (67%) 14 (70%) 5 (63%) 8 (47%)
Age (y) Mean 6 SD 66 6 8 39 6 17 49 6 11 64 6 11
doi:10.1371/journal.pmed.0050093.t002
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recommended by the manufacturer of the arrays (Agilent
Technologies). The cDNA was used as a template to generate
Cy3-labeled cRNA that was used for hybridization on Agilent
Whole Human Genome 4X 44K multipack arrays (Agilent
Technologies). After hybridization, scanning, and feature
extraction, data files were imported into a microarray
database and linked with updated gene annotations using
SOURCE (http://genome-www5.stanford.edu/cgi-bin/SMD/
source/sourceSearch) and then normalized using cyclic
LOESS [26]. Differentially expressed genes were identified
using significant analysis of microarrays (SAM) [27]. Probes
corresponding to the 49 protein markers were identified
through their gene symbols. Expression levels for the probes
that corresponded to these markers were extracted. In the
case of redundant probes, those with the highest expression
level and with the lowest Q-value were selected for
presentation.
Statistical Analysis
A protein was considered differentially expressed when
there was a change of at least 25% in concentration and
statistical significance at p , 0.05 corrected for multiple
testing. Data are reported as mean 6 standard deviation. The
Wilcoxon rank-sum test was used to identify potential
biomarkers that univariately distinguish IPF samples from
controls. For multiple testing the Bonferroni method was
used to control the family-wise error rate at 5%. Data were
analyzed using the R language for statistical computing
(http://www.r-project.org/) [28]. Classification and regression
trees (CART) methodology was used to identify potential
combinations of peripheral blood biomarkers that could be
used to distinguish IPF from controls. CART was performed
using the rpart package for recursive partitioning. Classi-
fication performance was assessed using the ROCR package
(http://rocr.bioinf.mpi-sb.mpg.de/). For oligonucleotide array
data analysis, we applied SAM [27]. Data visualization and
clustering were performed using Genomica (http://genomica.
weizmann.ac.il/index.html) [29] and Spotfire Decision Site 9
(TIBCO).
Results
Plasma Proteins Distinguish IPF Patients from Controls in
Derivation Cohort
Of 49 markers analyzed, 48 are detectable in plasma (Figure
1A); univariate analysis identified 12 proteins that are
differentially expressed in IPF compared to controls (Table
3). Five MMPs (MMP7, MMP1, MMP3, MMP8, MMP9), two
chemokines (CXCL10, CCL11), FAS, IL12B, and the soluble
TNF receptors (TNFRSF1A, TNFRSF1B) are significantly
overexpressed; AGER is significantly underexpressed in
plasma of patients with IPF compared to controls. MMP7
and MMP1, which have previously been shown to play a role
in IPF pathogenesis, are the top-ranked proteins in univariate
analysis (Table 3). Significant differences persist when age,
gender, or smoking status is statistically controlled.
To determine whether combinations of these plasma
proteins correctly classify IPF patients, we applied recursive
partitioning to the entire set of 49 markers and found that
plasma protein profiles clearly distinguish IPF patients from
normal controls. CART analysis showed that MMP7 and
MMP1, in addition to being the two most significant
biomarkers, are key components of a combinatorial classifier
that also includes MMP8, IGFBP-1, and TNFRS1A (Figure
1B). Sensitivity and specificity of the classifier are 98.6%
(95% confidence interval [CI] 92.7%–100%) and 98.1% (95%
CI 89.9%–100%), respectively. High concentrations of MMP7
alone (1.99 ng/ml) correctly classify 69 of 74 IPF patients
(93.2%) but incorrectly classify five normal samples as IPF
and five IPF samples as controls, whereas the combination of
high plasma concentrations of both MMP7 (1.99 ng/ml) and
MMP1 (2.15 ng/ml) excludes all controls. Thus the
combination of high MMP7 and high MMP1 concentrations
can distinguish IPF patients from controls. Receiver operat-
ing characteristic curves (ROCs) (Figure 1C) confirm that
MMP7 is the best univariate classifier, although the combi-
nation of five markers performs somewhat better (Figure 1C),
as does the combination of MMP7 and MMP1 (unpublished
data).
MMP7 and MMP1 Are Increased in the Lung and BAL Fluid
of Patients with IPF
To determine whether protein concentration differences
in peripheral blood reflect gene expression differences
present in the lung, we analyzed gene expression patterns
in 23 IPF and 14 control lungs using oligonucleotide
microarrays (Figure 2A). Of the five plasma proteins in the
CART plasma signature (Figure 1B), only the genes for MMP7
and MMP1 are significantly overexpressed in IPF lungs
compared to controls (SAM Q value ¼ 0 for both genes; 7.3-
and 15.7-fold increase, respectively). Of the ten other
proteins that are significantly different in the plasma of
patients with IPF (Table 3), the genes for MMP3, AGER, and
IL12B are also significantly differentially expressed in IPF
lungs (Figure 2A).
To determine whether MMP7 and MMP1 proteins are
secreted into the alveolar microenvironment, we measured
their concentrations in BAL obtained from 22 patients with
IPF and ten control individuals. MMP7 and MMP1 BAL
concentrations are significantly higher in IPF patients when
compared to controls (p, 0.00001 and p¼0.018, respectively)
(Figure 2B and 2C). Hence, elevated MMP7 and MMP1 levels
in the lung microenvironment are the most likely source for
their increased concentrations in peripheral blood.
MMP7 and MMP1 Are Not Increased in Patients with
COPD or Sarcoidosis
To determine whether concentrations of MMP7 and MMP1
are increased in other common chronic lung diseases, we
measured plasma concentrations in patients affected with
sarcoidosis or COPD. The 47 sarcoidosis patients were
stratified into those with evidence for parenchymal lung
disease (stage 2 or greater; n ¼ 29) and those with no lung
parenchymal involvement (n ¼ 18). As shown in Figure 3,
there are no significant differences in plasma concentrations
of MMP7 (p¼0.78) (Figure 3A) or MMP1 (p¼0.27) (Figure 3B)
between the sarcoidosis groups with or without lung
abnormalities when compared to controls. COPD partici-
pants were grouped by GOLD class, into 0–I (n ¼ 13), II (n ¼
21), and III–IV (n ¼ 39). No significant differences are found
in plasma concentrations of MMP7 (p ¼ 0.21) or MMP1 (p ¼
0.85) between groups of COPD patients stratified by GOLD
class (Figure 3A and 3B, respectively).
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MMP7 and MMP1 Are Significantly Higher in the Serum of
Patients with IPF Compared to Patients with HP
To determine whether peripheral blood concentrations of
MMP7 and MMP1 distinguish IPF from other common forms
of ILD, we measured their levels in 41 patients with HP and
34 patients with IPF. Univariately, serum concentrations of
MMP7 (p ¼ 0.01) and MMP1 (p , 0.001) are significantly
higher in IPF compared to HP; fold changes for MMP1 and
MMP7 are 2.3 and 1.31, respectively (Figure 4A and 4B).
Similar results are observed in a reanalysis of a previously
published DNA microarray dataset comparing gene expres-
sion in lung tissue obtained from IPF and HP patients [18]. In
this reanalysis, MMP7 and MMP1 levels are significantly
higher in IPF compared to HP (false discovery rate [FDR] ,
5%), however, as observed in the peripheral blood, the
change in MMP7 levels is moderate when compared to the
increase in MMP1 (Figure 4C).
Combinations of serum MMP1 and MMP7 concentrations
have positive predictive values for determining that a patient
has IPF ranging from 91% (MMP7 . 2.6 ng/ml and MMP1 .
8.9 ng/ml) to 66%, and negative predictive value (ruling out
IPF) ranging from 96% (MMP7 , 2.9 ng/ml and MMP1 .
Figure 1. Peripheral Blood Proteins Distinguish IPF Patients from Controls
(A) Heatmap of proteins measured in the plasma of IPF and control patients. Columns, individual patients; rows, proteins. Every protein level was
divided by the geometric mean of values for the same proteins for all patients and log based 2 transformed. Increasing shades of yellow, increased;
increased shades of purple, decreased; gray, unchanged. Proteins were clustered using Genomica. Red vertical line, cluster of proteins increased in IPF;
green vertical line, cluster of proteins decreased in IPF.
(B) Classification tree obtained by CART applied to plasma protein concentration data from IPF patients and controls. A blue box identifies a terminal
node as control; a red box as IPF. All counts are listed as control/IPF. Concentrations are in ng/ml. In the subgroup with high MMP7 concentration but
low MMP1 concentration (14 IPF samples, five control samples), splitting on IGFBP1 and TNFRSF1A improves classification, while in the subgroup with
low MMP7, MMP8 improves classification.
(C) ROC curves for using each of five markers, or their combination, to classify samples as IPF or control. Sensitivity, or true positive rate, is plotted on
the y-axis, and false positive rate, or 1 specificity, on the x-axis. The area under each ROC curve is equivalent to the numerator of the Mann-Whitney U-
statistic comparing the marker distributions between IPF and control samples. The magenta line labeled ‘‘Combined’’ is for the combinatorial classifier
using all five markers. The identity line at 45 8 represents a marker that performed no better than classifying samples as IPF or control by flipping a fair
coin.
doi:10.1371/journal.pmed.0050093.g001
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3.5ng/ml) to 70% (Figure 4D). Additionally, the combination
of high MMP7 and high MMP1 peripheral blood concen-
trations distinguish IPF from HP with 96.3% sensitivity (95%
CI 81.0%–100%) and 87.2% specificity (95% CI 72.6%–
95.7%) (Figure 4E), further supporting that MMP1 in
combination with MMP7 distinguishes IPF from HP.
MMP7 and MMP1 Are Significantly Higher in the Serum of
an Independent Validation Cohort
To verify our findings, we measured serum concentrations
of MMP7 and MMP1 in an independent validation cohort
comprised of patients affected with IPF, familial pulmonary
fibrosis, or subclinical ILD, and control individuals. This
cohort has been recently described by us [21]. Even though
concentrations were measured in serum and not plasma,
significantly higher concentrations of MMP7 and MMP1 are
found in patients with pulmonary fibrosis compared to
controls (p , 0.001 and p ¼ 0.01, respectively). Notably,
serum MMP7 concentrations in patients with subclinical ILD
are significantly higher compared to control individuals (p ¼
0.019) and significantly lower compared to patients with full-
blown IPF (p , 0.0001) (Figure 5A), suggesting that MMP7
may serve as a biomarker for disease progression. There is no
significant difference in MMP7 concentrations between
patients with familial or sporadic IPF, consistent with the
findings of Yang et al. [30].
In this cohort, elevated MMP1 concentrations combined
with high concentrations of MMP7 can distinguish IPF from
controls with 89.2% sensitivity (95% CI 71.8%–91.7%) and
95.0% specificity (95% CI 75.1%–99.9%), supporting the
findings in our derivation cohort (Figure 5B).
MMP7 Concentrations Correlate Moderately with Disease
Severity
To determine whether concentrations of MMP7 or MMP1
correlate with disease severity, we compared pulmonary
function measurements with serum concentrations of
MMP7 and MMP1 in the validation cohort. We found a
significant correlation between higher MMP7 concentrations
and disease severity as measured by FVC% (Figure 5C) and
DLCO% (Figure 5D). Fitted models predict a decline of 4.1%
in DLCO% (p¼ 0.002, r¼0.53) and 4.0% in FVC% (p¼ 0.002,
r¼0.51) for each increment of 1 ng/ml in serum MMP7. We
did not find any statistically significant correlation between
Table 3. Plasma Proteins That Distinguish IPF from Controls
Protein Fold p-Value
MMP1 4.6 ,0.000001
MMP7 3.2 ,0.000001
MMP8 2.6 ,0.000001
CXCL10 2.3 ,0.000001
MMP9 2 ,0.000001
TNFRSF1A 1.8 ,0.000001
MMP3 1.8 ,0.000001
AGER 0.66 ,0.000001
FAS 1.7 ,0.001
CCL11 1.7 ,0.001
TNFRSF1B 1.4 ,0.001
IL12B 1.3 ,0.001
doi:10.1371/journal.pmed.0050093.t003
Figure 2. MMP7 and MMP1 Gene and Protein Levels Are Significantly Increased in the Lungs of Patients with IPF
(A) Average gene expression levels (log scale) measured using gene expression microarrays of genes that encode the 49 protein markers in IPF lungs (y-
axis) compared to control lungs (x-axis). Colored squares (black or red) are genes that encode proteins that changed significantly in plasma. Red squares
are genes that changed significantly (SAM Q value ,5%) in gene expression data and that encode proteins measured in peripheral blood. Green
oblique lines denote 2-fold change.
(B and C) MMP7 (B) and MMP1 (C) concentrations (ng/ml) are significantly (p , 0.00001 and p¼ 0.018, respectively) higher in BAL fluid of patients with
IPF (n¼ 22) compared to control individuals (n¼ 10).
doi:10.1371/journal.pmed.0050093.g002
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MMP1 concentrations and pulmonary function measure-
ments (unpublished data).
Discussion
Overall, our study demonstrates the first evidence for a
peripheral blood protein signature in IPF patients to our
knowledge. MMP7 and MMP1, two matrix metalloproteases
previously implicated in the pathogenesis of IPF [31], are
significantly increased in plasma, serum, BAL fluid, and lung
tissue of IPF patients, suggesting that increased MMP7 and
MMP1 levels in the peripheral blood are indicative of the
pathologic changes that characterize the IPF alveolar micro-
environment. Used in combination, blood levels of MMP1
and MMP7 can distinguish IPF patients from diverse types of
chronic lung disease including HP, a common interstitial
pneumonia that can sometimes be indistinguishable from IPF
[32–34]. Increases in MMP7 blood concentrations are
observed in patients with subclinical familial pulmonary
fibrosis, and higher levels of MMP7 are associated with disease
severity. Taken together our findings support the use of
MMP1 and MMP7 as IPF biomarkers and suggest that their
role in diagnosis, early detection, and monitoring of disease
progression should be further investigated.
Multiple MMPs are among the 12 proteins significantly
increased in the blood of IPF patients. The roles of MMPs
have been intensively studied and debated in IPF [35]. While
multiple and often contrasting roles have been proposed for
MMPs in regulating abnormal epithelial response to injury,
fibroblast proliferation, extracellular matrix accumulation,
and aberrant tissue remodeling, the consensus is that this
family of matrix degrading enzymes is involved in disease
pathogenesis [31,36–40]. The two top-ranked proteins in this
study are MMPs known to be significantly overexpressed in
the activated alveolar epithelium in IPF lungs. MMP1, a
matrix metalloprotease that primarily degrades fibrillar
collagen, is rarely expressed under normal conditions, but is
highly overexpressed in reactive alveolar epithelial cells in
IPF lungs [39]. MMP7, a matrix metalloprotease with multiple
local inflammatory regulatory roles [41,42], is also highly
upregulated in alveolar epithelial cells in IPF [39,43].
Furthermore, MMP7 knockout mice are relatively protected
from bleomycin-induced fibrosis [39], suggesting that MMP7
may have a profibrotic effect in IPF. Taken in the above
context, our results strongly suggest that activated epithelial
cells in IPF lungs are the likely source of elevated peripheral
blood concentrations of MMP1 and MMP7, thus supporting
their use as biomarkers for disease detection and progression.
Our data show that neither patients with COPD, a chronic
progressive lung disease, nor patients with sarcoidosis, a
chronic granulomatous ILD, express significantly increased
peripheral blood concentrations of MMP7 or MMP1. Further,
elevated peripheral blood MMP1 concentrations, in the
presence of elevated MMP7 concentrations, distinguish IPF
from HP. A similar trend in gene expression of MMP7 and
MMP1 is found in the lungs of patients with IPF and HP,
further supporting the notion that the changes in peripheral
blood concentrations of MMP7 and MMP1 are reflective of
the lung gene environment and constitute a disease-specific
signal. This finding may be very important clinically, because
subacute HP is frequently misdiagnosed as idiopathic non-
specific interstitial pneumonia (NSIP), and in its chronic
advanced form HP can be undistinguishable from IPF [32–
34]. In fact, recent studies have demonstrated that histopa-
thologic and HRCT abnormalities observed in chronic HP
often overlap with those of usual interstitial pneumonia
(UIP), representing an important challenge to the differential
diagnosis of these conditions [33,34,44]. Thus, the elevated
peripheral blood concentrations of MMP7 and MMP1
observed in IPF are not due to a systemic stress response to
a chronic lung disease and distinguish COPD, sarcoidosis, and
HP from IPF. While we do not advocate at this stage relying
solely on peripheral blood concentrations of MMP7 and
MMP1 in distinguishing IPF from HP, sarcoidosis, or the less
difficult differential diagnosis of COPD, it seems likely that
knowing these concentrations will impact clinical decision-
making.
We did not compare IPF to other idiopathic interstitial
pneumonias such as NSIP. There is nothing in our data to
suggest that we can distinguish IPF from these diseases using
MMP7 and MMP1 peripheral blood concentrations. In fact
Figure 3. MMP7 and MMP1 Plasma Concentrations Are High in IPF, but Not Sarcoidosis or COPD
Concentrations (ng/ml) of MMP7 (A) and MMP1 (B) are significantly higher in patients with IPF (n ¼ 74; p , 0.00001 and p ¼ 0.018, respectively),
compared to controls (n¼ 53), but not sarcoidosis (n¼ 47; p¼ 0.78 and p¼ 0.28, respectively), compared to controls (n¼ 53) or COPD (n¼ 73; p¼ 0.21
and 0.85, respectively, stratified by GOLD class, as 0–I, II, and III–IV).
doi:10.1371/journal.pmed.0050093.g003
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the finding of elevated MMP7 in patients with subclinical ILD
may be indicative that this increase may be present in other
idiopathic ILDs. Furthermore, gene expression patterns were
found to be extremely similar in IPF and NSIP [30,45], and
BAL MMP7 levels were also recently found to be similar in
patients with IPF and NSIP [46]. The major limitation in these
studies was the small number of cases with NSIP because of
the substantial rarity of isolated NSIP. Therefore our results
should encourage the establishment of multicenter collec-
tions of peripheral blood samples of patients with ILD with
sufficient power to determine whether NSIP and IPF differ in
their peripheral blood protein expression.
In comparison to other studies, major attributes of our
analysis include the relatively large size of our derivation
cohort and the large number of proteins assayed in this
cohort of patients with IPF, the comparison of peripheral
blood biomarker levels with their gene expression levels in
the lungs and BAL, the comparison with multiple relatively
large control populations with other chronic lung diseases to
establish specificity of our findings, and the verification of
our initial results in an independent validation cohort. A
unique feature of our validation cohort is that it contains
patients with subclinical ILD who are asymptomatic first-
degree relatives of patients affected with familial IPF. These
individuals have HRCT findings of early ILD, but do not have
pulmonary function abnormalities, cough, or dyspnea [19,21].
Analysis of samples from this cohort allowed us to demon-
strate that MMP7 concentrations are significantly higher in
patients with early subclinical lung disease, suggesting that
MMP7 may be a marker for early asymptomatic ILD.
Peripheral blood concentrations of MMP7 also correlate with
pulmonary function tests, which are surrogate measures of
disease severity and thus may reflect molecular mechanisms
of lung remodeling in IPF [31]. Naturally, the use of different
platforms and different sample types limits our ability at this
stage to set a disease-specific MMP concentration threshold.
Figure 4. MMP7 and MMP1 Serum Concentrations Are Higher in IPF, Compared to HP
(A and B) Concentrations (ng/ml) of MMP7 (A) and MMP1 (B) in the blood are significantly higher in patients with IPF (n¼34) than in patients with HP (n
¼ 41).
(C) Average gene expression levels (log scale) in IPF samples (y-axis) compared to HP (x-axis) measured by gene expression microarrays. Gray circles, all
genes on the array; red circles, MMP1 and MMP7. Green oblique lines denote 2-fold change.
(D) Combinations of serum MMP7 (y-axis) and MMP1 concentrations (x-axis) in IPF (closed circles) and HP patients (open circles). Corners represent
points in which the trade-off between positive predictive value (PPV) and negative predictive value (NPV) are optimal for ruling out IPF (blue) or
concluding IPF (red) on the basis of MMP1 and MMP7 concentrations.
(E) ROC curves for using MMP1 or MMP7, or their combination, to classify samples as IPF or HP. Sensitivity, or true positive rate, is plotted on the y-axis,
and false positive rate, or 1 specificity, on the x-axis. The identity line at 45 8 represents a marker that performed no better than classifying samples as
IPF or HP by flipping a fair coin.
doi:10.1371/journal.pmed.0050093.g004
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However, the reproducibility and concordance of our results
across different sample types and in multiple cohorts suggest
that such a threshold can and should be determined.
In conclusion, in this study we report for the first time to
our knowledge the presence of a peripheral blood protein
signature in a disease that is confined to the lung. This
signature is composed of MMPs, TNF receptors, and some
chemokines. Our data demonstrate that peripheral blood
increases in two of these markers (MMP1 and MMP7) are also
observed in lung and may be specific to IPF. We provide
verification of our observations in an independent validation
cohort and show that MMP7 correlates with disease severity
and is increased in patients with subclinical ILD. While
additional studies will determine the value of this protein
signature in clinical practice, our results support a potential
value of peripheral blood proteins as biomarkers in an organ-
confined disease such as IPF. If validated, these biomarkers
have the potential to greatly facilitate the introduction of
new therapies in IPF and to profoundly affect the manage-
ment of these patients.
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Editors’ Summary
Background. Idiopathic pulmonary fibrosis (IPF) is a serious disease in
which the lungs become progressively scarred or thickened for unknown
reasons. In healthy people, air is taken in through the mouth or nose and
travels down the windpipe into tubes in the lungs called the airways.
Each airway has many small branches that end in alveoli, tiny air sacs
with thin walls that are surrounded by small blood vessels called
capillaries. When air reaches the alveoli, the oxygen in it passes into the
bloodstream and is taken to the organs of the body to keep them
working. In IPF, the alveoli and the space around them (the ‘‘interstitial’’
area) gradually become scarred and thickened, which stops oxygen’s
movement into the bloodstream. When only small areas of the lung are
scarred, IPF may cause no symptoms. But, as more of the lung becomes
damaged, IPF eventually causes breathlessness, even when resting.
There is no effective treatment for IPF, although steroids and drugs that
suppress the body’s immune system are often tried in an attempt to slow
its progression. On average, half of the people with IPF die within three
years of diagnosis, often from respiratory or heart failure.
Why Was This Study Done? It can be difficult to diagnose IPF—there
are many lung diseases with similar symptoms, including numerous
other interstitial lung diseases—and currently, physicians can only follow
the progression of IPF by repeatedly testing their patients’ lung function
or by doing multiple chest X-rays. If proteins could be identified whose
level in blood indicated disease activity (so-called ‘‘peripheral blood
biomarkers’’), it would be easier to diagnose and monitor patients. In
addition, the identification of such biomarkers might suggest new drug
targets for the treatment of IPF. In this study, the researchers look for
peripheral blood biomarkers in IPF by using a ‘‘multiplex analysis’’
system to measure the level of several proteins in patient blood samples
simultaneously.
What Did the Researchers Do and Find? The researchers measured the
levels of 49 plasma proteins (plasma is the fluid part of blood) in 74
patients with IPF and 53 healthy people (controls) and used a technique
called ‘‘recursive partitioning’’ to define a five-protein signature that
distinguished patients from unaffected study participants (controls).
Matrix metalloproteinase 7 (MMP7) and MMP1—the two plasma proteins
whose levels were most increased in patients with IPF compared to
controls—were key components of this signature. Concentrations of
MMP7 and MMP1 were higher in bronchoalveolar lavage samples (fluid
obtained by washing out the lungs with saline) and in lung tissue
samples from patients with IPF than in similar samples taken from
healthy individuals. Plasma concentrations of MMP7 and MMP1 were
significantly higher in patients with IPF than in patients with hyper-
sensitivity pneumonitis, an interstitial lung disease that mimics IPF, but
not increased in patients with chronic obstructive pulmonary disease or
sarcoidosis, two other lung diseases. In an independent validation group,
patients with IPF and familial pulmonary fibrosis had increased plasma
concentrations of MMP7 and MMP1 that correlated with the severity of
their disease. In addition, MMP7 concentrations were raised in close
relatives of people with familial pulmonary fibrosis who had normal lung
function tests but some lung scarring.
What Do These Findings Mean? These findings provide evidence for a
protein signature in the blood for IPF and suggest MMP1 and MMP7 may
be useful as biomarkers for IPF. These two matrix metalloproteinases
have previously been suggested to be involved in the development of
IPF. However, additional work is probably needed to confirm that
increased plasma concentrations MMP7 and MMP1 are specific for IPF,
since it may be that these markers will not distinguish IPF from other
interstitial lung diseases.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050093.
 Read a related PLoS Medicine Perspective article
 The MedlinePlus Encyclopedia has a page on idiopathic pulmonary
fibrosis (in English and Spanish) and on pulmonary fibrosis
 The US National Heart Lung and Blood Institute and the British Lung
Foundation also provide information on IPF for patients and relatives
 Some of the researchers involved in this study provide more details
about what might go wrong in IPF in a recent PLoS Medicine article
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